The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: The return of bird flu and the effects of pandemic fatigue
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Pharma blockbusters, pandemic policy, & legal chicanery
The Readout LOUD Adam Feuerstein and Meg Tirrell Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein #JPM23 in review, the year ahead, & the merits of Miami
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Leaky health data, ASH22, & what it takes to get booed by your peers
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein The ‘electric vehicles’ of pharma, Illumina’s boondoggle, & a Theranos sentencing
The Readout LOUD Adam Feuerstein, Damian Garde and Allison DeAngelis Listen: Whither PhRMA, Alzheimer’s treatment data revealed, and the first fecal microbiome drug approval
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Roche’s failure, Eisai’s success, and a live AMA
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Biogen’s new CEO, how the midterms affect science, & a biotech bankruptcy
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: How the biotech revolution could come apart at the seams
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein BU’s Covid tinkering, FDA on trial, & why it’s hard to take drugs off the market
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein BIO’s messy transition, mRNA’s future, & Biogen’s next CEO
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Nobels for science, biotech dealmaking, & a friendly FTC
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: A surprise success in Alzheimer’s and how FDA history seeded modern controversy
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Pharma’s telehealth gold mine, the return of the biotech IPO, & a merger deferred
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: The anti-aging research boom, the Godfather of biotech, & the future of Biogen
The Readout LOUD Damian Garde and Allison DeAngelis Fauci’s non-retirement, grading biotech VCs, & a bellwether IPO
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Private equity in autism care, a watershed FDA approval, and the future of ALS treatment
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: The last-minute push for drug pricing reform, Alnylam’s success, and Sarepta’s gamble
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer’s data
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Well-paid CEOs, behind the scenes at Moderna, & Biogen’s CEO search
The Readout LOUD Damian Garde and Adam Feuerstein Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’